Skip to main content
OpenTrials
Completed

NCT Number: NCT05195437

Evolution of the Quality of Life of Short Statured Children Treated With Growth Hormone : Evaluation at Adult Size

Short stature can lead to emotional and social stress in children and adolescents, as well as their parents. Children and their parents want to be able to identify the cause of stunted growth and address it with treatment. Mitigating the impact of short stature on quality of life is one of the main goals of treatment. The quality of life in children can be measured using adapted self-questionnaires.

The investigative team published in 2019 the results of a preliminary study which shows that after one year of treatment with growth hormone, the quality of life improves in children, in particular on the scales emotional and social. These evaluations were carried out in particular thanks to the general questionnaire of quality of life: Pediatric Quality of Life Inventory (PedsQL) 4.0, but also via a specific questionnaire of the size: Quality of Life of Short Stature Youth questionnaire (QoLiSSY).

50 of the 74 patients who participated in this study have now reached their final height. The objective of the present study is to reassess this cohort using the QoLiSSY and PedsQL 4.0 questionnaires. The patient will be his own witness.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Growth Hormone Treatment

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Necker-Enfants Malades

Paris, 75015, France

About this study

Short stature can lead to emotional and social stress in children and adolescents, as well as their parents. Children and their parents want to be able to identify the cause of stunted growth and address it with treatment. Mitigating the impact of short stature on quality of life is one of the main goals of treatment. The quality of life in children can be measured using adapted self-questionnaires.

The investigative team published in 2019 the results of a preliminary study which shows that after one year of treatment with growth hormone, the quality of life improves in children, in particular on the scales emotional and social. These evaluations were carried out in particular thanks to the general questionnaire of quality of life: Pediatric Quality of Life Inventory (PedsQL) 4.0, but also via a specific questionnaire of the size: Quality of Life of Short Stature Youth questionnaire (QoLiSSY).

50 of the 74 patients who participated in this study have now reached their final height. The objective of the present study is to reassess this cohort using the QoLiSSY and PedsQL 4.0 questionnaires. The patient will be his own witness.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital and treated with growth hormone because of their short stature.
  • Patient who participated in the initial study.
  • Patient having reached the final height during the last consultation (growth rate less than 1 cm / year and / or bone age ≥ 15 years for girls, ≥ 17 years for boys).
  • Holders of parental authority, minor patients and adult patients informed and not opposed to their participation in the study.

Exclusion criteria

  • Refusal to participate in the study.

Treatment and study plan

QoLiSSY and PedsQL 4.0 questionnaires

Other

Patients have been reaching adult size complete the two questionnaires of the study :

Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.

Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.

The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy.

Primary outcomes

  1. Evolution of the quality of life

    Time frame: Day 0

    Evolution of the quality of life in short patients who have been treated with growth hormone. Comparison of the scores of the initial Quality of Life in Short Stature Youth (QoLiSSY) questionnaire (start of growth hormone treatment) compared to the scores obtained when the patients reached their final height. QoLISSY questionnaires include two different forms: parent questionnaire (children aged 4 to 18 years of age) and child questionnaire (only for children ≥8 years of age). Both questionnaires have 50 items that cover three core domains (physical, emotional, and social), and additional complementary domains. The parent questionnaire includes two additional scales (16 items) assessing parental stress and anxiety. Scores are converted in SD scores and compared to age- and gender-specific data from a reference population of children and adolescents with short stature. A total score is computed as the mean score on the three core scales.

Secondary outcomes

  1. Adult-size quality of life

    Time frame: Day 0

    Change in scores for the two questionnaires QoLISSY and Pediatric Quality of Life Inventory (PedsQL) 4.0 at adult size.

    Children younger than 8 years of age completed the questionnaire PedsQL 4.0 with their parents. The PedsQL has 23 items that investigate physical, emotional, and social QoL, as well as school functioning. This tool has been validated in the 2- to 18-year age range. The parents complete the questionnaire if the child is younger than 5 years. After that age, the child completes the age-appropriate version of the questionnaire (5-7, 8-12, or 13-18 years). The score is expressed as a percentage, with scores from 0 to 100%, 100% being the best score. Questionnaire subscales are considered evaluable if answers are provided for at least 80% of the items. High results being associated with a better quality of life related to health.

  2. Correlation between quality of life changes and clinical response to growth hormone therapy

    Time frame: Day 0

    Correlation between the changes in scores on the 2 questionnaires QoLISSY and PedsQL 4.0 at adult size and number of centimeters taken since the start of growth hormone treatment.

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Evolution of the Quality of Life of Short Stature Children Treated With Growth Hormone : Evaluation at Adult Size

Acronym: HF QoL

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 19, 2022
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.